RECURRENT PLASMA CELL MYELOMA

This early-stage study tests whether adding a lab-modified virus (pelareorep) to a standard drug combination (bortezomib, dexamethasone, and pembrolizumab) is safe and effective for people with multiple myeloma that has returned or is not responding to treatment. About 10 partici…

This early-stage trial tests a new treatment for multiple myeloma that has returned or stopped responding to standard therapies. The treatment uses a patient's own immune cells (T-cells) that are trained in the lab to recognize and attack cancer cells carrying a protein called MU…

This early-phase study tests the safety and best dose of two drugs, venetoclax and tocilizumab, in people with a specific genetic subtype of multiple myeloma (t(11;14)) that has returned or stopped responding to treatment. The trial includes both African American and non-African …

This study tests a specific schedule of chemotherapy drugs (busulfan and fludarabine) followed by a donor stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. After the transplant, a drug called cyclophosphamide is given to help prevent the don…

This study tests a combination of three drugs (isatuximab, carfilzomib, and pomalidomide) in people with multiple myeloma that has come back or no longer responds to treatment. The goal is to see if this mix can shrink or control the cancer. The trial enrolled 5 adults and is no …

This early-phase trial is testing a combination of two drugs—selinexor and choline salicylate—in 22 adults with certain blood cancers (lymphoma, multiple myeloma, or histiocytic/dendritic cell tumors) that have come back or not responded to prior treatment. The main goal is to fi…

This study tests a two-step treatment plan for people with multiple myeloma that has come back or stopped responding to therapy. First, patients receive daratumumab, bortezomib, and dexamethasone, then switch to daratumumab, ixazomib, and dexamethasone. The goal is to see if this…

This study looks at how often cancer patients in a supportive care clinic experience cachexia (unintentional weight loss and loss of appetite) and the emotional burden it places on both patients and their primary caregivers. Researchers will track weight changes and use questionn…